DK1419154T3 - Rapamycin-29-enoler - Google Patents
Rapamycin-29-enolerInfo
- Publication number
- DK1419154T3 DK1419154T3 DK02768642T DK02768642T DK1419154T3 DK 1419154 T3 DK1419154 T3 DK 1419154T3 DK 02768642 T DK02768642 T DK 02768642T DK 02768642 T DK02768642 T DK 02768642T DK 1419154 T3 DK1419154 T3 DK 1419154T3
- Authority
- DK
- Denmark
- Prior art keywords
- enols
- rapamycin
- useful
- treatment
- solid tumors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31421101P | 2001-08-22 | 2001-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1419154T3 true DK1419154T3 (da) | 2006-01-09 |
Family
ID=23219037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02768642T DK1419154T3 (da) | 2001-08-22 | 2002-08-21 | Rapamycin-29-enoler |
Country Status (12)
Country | Link |
---|---|
US (1) | US6677357B2 (fr) |
EP (1) | EP1419154B1 (fr) |
JP (1) | JP2005501868A (fr) |
CN (1) | CN1310908C (fr) |
AT (1) | ATE305932T1 (fr) |
BR (1) | BR0211986A (fr) |
CA (1) | CA2455308A1 (fr) |
DE (1) | DE60206512T2 (fr) |
DK (1) | DK1419154T3 (fr) |
ES (1) | ES2246409T3 (fr) |
MX (1) | MXPA04001524A (fr) |
WO (1) | WO2003018573A1 (fr) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60231868D1 (de) * | 2001-04-24 | 2009-05-20 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
US20030176455A1 (en) * | 2002-03-13 | 2003-09-18 | Wyeth | Method of inhibiting cell death |
DE60326833D1 (de) * | 2002-05-15 | 2009-05-07 | Endocyte Inc | Vitamin-mitomycin-konjugate |
ATE385795T1 (de) | 2002-07-30 | 2008-03-15 | Wyeth Corp | Parenterale formulierungen mit einem rapamycin hydroxyester |
EP2529758A3 (fr) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Conjugués d'administration de médicaments à liaison au récepteur de vitamines |
WO2004089369A2 (fr) * | 2003-04-11 | 2004-10-21 | Cambridge University Technical Services Limited | Methodes et moyens permettant de traiter des troubles de conformation des proteines |
US7349971B2 (en) * | 2004-02-05 | 2008-03-25 | Scenera Technologies, Llc | System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information |
US8288557B2 (en) | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
AU2005294382A1 (en) * | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
US8021849B2 (en) | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
US7632307B2 (en) * | 2004-12-16 | 2009-12-15 | Advanced Cardiovascular Systems, Inc. | Abluminal, multilayer coating constructs for drug-delivery stents |
RU2007119585A (ru) | 2004-12-20 | 2009-01-27 | Вайет (Us) | Производные рапамицина и их применение при лечении неврологических заболеваний |
US7276498B2 (en) | 2004-12-20 | 2007-10-02 | Wyeth | Rapamycin analogues and uses thereof in the treatment of neurological disorders |
CA2595766A1 (fr) | 2005-02-09 | 2006-08-17 | Wyeth | Polymrophe de cci-779 et utilisation de ce dernier |
BRPI0608885A2 (pt) * | 2005-03-07 | 2017-02-21 | Wyeth Corp | composto de isômero c de sdz-rad, composição farmacêutica, e, embalagem farmacêutica |
EP1859274A2 (fr) * | 2005-03-07 | 2007-11-28 | Novartis AG | Genes associes a des etats neurodegeneratifs |
US8044200B2 (en) * | 2005-03-16 | 2011-10-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
US7189582B2 (en) * | 2005-04-27 | 2007-03-13 | Dade Behring Inc. | Compositions and methods for detection of sirolimus |
JP2008539276A (ja) * | 2005-04-27 | 2008-11-13 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法 |
WO2007022493A2 (fr) * | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Conjugues de ligand d'alcaloides vinca, analogues et derives |
KR101364912B1 (ko) * | 2005-08-19 | 2014-02-21 | 엔도사이트, 인코포레이티드 | 복수-약제 리간드 공액체 |
PE20071067A1 (es) * | 2005-12-20 | 2007-11-26 | Wyeth Corp | Composiciones de rapamicina y cci-779 y metodo para su preparacion |
US8430055B2 (en) * | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080276935A1 (en) * | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US20080175887A1 (en) * | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US20100104626A1 (en) * | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
NZ580132A (en) * | 2007-03-14 | 2012-11-30 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins to vitamins |
JP2008305262A (ja) * | 2007-06-08 | 2008-12-18 | Konica Minolta Business Technologies Inc | サーバ及びシンクライアント環境でのプリンタ紹介方法 |
AU2008268432B2 (en) * | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
EP2209374B1 (fr) | 2007-10-25 | 2014-12-03 | Endocyte, Inc. | Tubulysines et leurs procédés de préparation |
US20120064143A1 (en) | 2008-11-11 | 2012-03-15 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
WO2015103447A1 (fr) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Préparations orales de nanoparticules de rapamycine, et utilisation |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
WO2013013708A1 (fr) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Traitement du rejet aigu dans une transplantation rénale |
EP2589383A1 (fr) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | Analogue de rapamycine spécifique au sous-type de FKBP à utiliser dans le traitement des maladies |
WO2013126797A1 (fr) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Ciblage du récepteur de la cholécystokinine de type b pour imagerie et thérapie |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
CN103705925B (zh) | 2012-09-29 | 2018-03-30 | 段磊 | 抑制PI3K/AKT/mTOR信号通路的药物组合 |
US9750728B2 (en) | 2012-09-29 | 2017-09-05 | Targeted Therapeutics, Llc | Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway |
WO2014059295A1 (fr) | 2012-10-12 | 2014-04-17 | The Board Of Regents Of The University Of Texas System | Utilisation d'inhibiteurs mtor pour traiter le déficit cognitif vasculaire |
CA2887727A1 (fr) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Conjugues d'administration de medicament contenant des acides amines artificiels et procedes d'utilisation |
WO2014160328A1 (fr) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Inhibiteurs de mtor pour la prévention de la croissance de polypes intestinaux |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
EP3131546B1 (fr) | 2014-04-16 | 2022-02-16 | Rapamycin Holdings, Inc. | Préparation orale de rapamycine pour utilisation dans le traitement de la gingivo-stomatite chronique féline (fcgs) |
WO2018213352A1 (fr) | 2017-05-15 | 2018-11-22 | C.R. Bard, Inc. | Dispositif médical à revêtement d'élution de médicament et à couche intermédiaire |
EP3880266A1 (fr) | 2018-11-14 | 2021-09-22 | Lutonix, Inc. | Dispositif médical avec revêtement à élution de médicament sur un dispositif à surface modifiée |
CN113939324A (zh) | 2019-04-08 | 2022-01-14 | 巴德外周血管股份有限公司 | 在经改性装置表面上具有药物洗脱涂层的医疗装置 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
EP0378318A1 (fr) * | 1989-01-11 | 1990-07-18 | Merck & Co. Inc. | Procédé pour la préparation de FK-506 ainsi que produits intermédiaires tricarbonyliques |
US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
GB2247456A (en) * | 1990-09-03 | 1992-03-04 | Fujisawa Pharmaceutical Co | Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same |
US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
US5078999A (en) | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
DE69209183T2 (de) | 1991-06-18 | 1996-08-08 | American Home Prod | Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen |
ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5621108A (en) * | 1994-12-05 | 1997-04-15 | Trustees Of The University Of Pennsylvania | Processes and intermediates for preparing macrocycles |
US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
CN1235608A (zh) * | 1996-09-09 | 1999-11-17 | 美国家用产品公司 | 烷基化的雷帕霉素衍生物 |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
EP1419153A1 (fr) | 2001-08-22 | 2004-05-19 | Wyeth | Dialdehydes rapamycine |
-
2002
- 2002-08-21 AT AT02768642T patent/ATE305932T1/de not_active IP Right Cessation
- 2002-08-21 DK DK02768642T patent/DK1419154T3/da active
- 2002-08-21 CA CA002455308A patent/CA2455308A1/fr not_active Withdrawn
- 2002-08-21 BR BR0211986-2A patent/BR0211986A/pt not_active IP Right Cessation
- 2002-08-21 ES ES02768642T patent/ES2246409T3/es not_active Expired - Lifetime
- 2002-08-21 JP JP2003523235A patent/JP2005501868A/ja active Pending
- 2002-08-21 CN CNB028163052A patent/CN1310908C/zh not_active Expired - Fee Related
- 2002-08-21 EP EP02768642A patent/EP1419154B1/fr not_active Expired - Lifetime
- 2002-08-21 DE DE60206512T patent/DE60206512T2/de not_active Expired - Fee Related
- 2002-08-21 MX MXPA04001524A patent/MXPA04001524A/es active IP Right Grant
- 2002-08-21 WO PCT/US2002/026622 patent/WO2003018573A1/fr active IP Right Grant
- 2002-08-22 US US10/224,971 patent/US6677357B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1545511A (zh) | 2004-11-10 |
CA2455308A1 (fr) | 2003-03-06 |
US6677357B2 (en) | 2004-01-13 |
DE60206512D1 (de) | 2006-02-16 |
CN1310908C (zh) | 2007-04-18 |
EP1419154A1 (fr) | 2004-05-19 |
ES2246409T3 (es) | 2006-02-16 |
DE60206512T2 (de) | 2006-06-22 |
MXPA04001524A (es) | 2004-05-31 |
BR0211986A (pt) | 2004-09-28 |
EP1419154B1 (fr) | 2005-10-05 |
WO2003018573A1 (fr) | 2003-03-06 |
JP2005501868A (ja) | 2005-01-20 |
US20030114477A1 (en) | 2003-06-19 |
ATE305932T1 (de) | 2005-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE305932T1 (de) | Rapanycin29-enole | |
MXPA04001523A (es) | Dialdehidos de rapamicina. | |
DE50306232D1 (de) | Ampholytisches copolymer und dessen verwendung | |
WO2002026746A3 (fr) | 1-oxorapamycines | |
YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
BR0113975A (pt) | ésteres de rapamicina solúveis em água | |
SG149063A1 (en) | Use of modified cyclosporins for the treatment of hcv disorders | |
NO20034056D0 (no) | Proliferative sykdommer | |
CO5611160A2 (es) | Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos | |
WO2002028867A3 (fr) | Ethers de 7-desmethylrapamycine | |
HUP0301835A2 (hu) | Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva | |
BRPI0307673A2 (pt) | métodos de tratar doença vascular. | |
EP1432714A4 (fr) | Composes chimiques | |
WO2003101401A3 (fr) | Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas | |
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
NO20055130D0 (no) | Aminocykloheksyleter-forbindelser og deres anvendelse | |
WO2002028866A3 (fr) | Hydroxyesters de 7-desmethylrapamycine | |
WO2001098317A3 (fr) | Alpha-glycosylceramides destines au traitement d'infections bacteriennes et fongiques | |
DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
WO2007059341A3 (fr) | Modulateurs de la proteine kinase a base de pyrazolothiazole | |
WO2004031129A3 (fr) | Nouveaux composes destines au traitement des maladies auto-immunes, des maladies immuno-allergiques et des rejets en cas de greffes d'organes ou de tissus | |
WO2004041158A3 (fr) | Compositions de rifalazil et regimes therapeutiques | |
WO2003051299A8 (fr) | Rifamycines au sulfhydryle et utilisations de ces dernieres | |
ATE399532T1 (de) | Medizinische seife | |
WO2004045545A3 (fr) | Compositions et procedes destines au traitement du cancer, au criblage des composants anticancereux presumes et a l'estimation de l'evolution du cancer |